Naïve CD4+ T cell

Naïve CD4+ T cells are mature T lymphocytes that have successfully undergone thymic selection but have not yet encountered their specific cognate antigen in the periphery (StatPearls, 2023). They are phenotypically identified by the expression of CD4, CD45RA, and lymphoid homing receptors such as CCR7 and CD62L, which facilitate their circulation through secondary lymphoid organs (Sallusto et al., Nature, 1999). Upon recognition of an antigen presented by MHC class II molecules, these cells undergo clonal expansion and differentiate into specialized effector subsets, including Th1, Th2, Th17, and follicular helper T cells, or into regulatory T cells (Janeway's Immunobiology, 2016). In disease states, they are the primary targets for HIV-1 entry and replication, leading to progressive immune depletion (NIH, 2023). Furthermore, the dysregulation of naïve CD4+ T cell differentiation is a hallmark of various autoimmune and inflammatory disorders. Therapeutic interventions often target the signaling pathways within these cells, such as the calcineurin or mTOR pathways, to prevent unwanted immune activation in transplantation or autoimmunity (PubChem, 2024).

Other names

Antigen-inexperienced CD4+ T cellCD4+ CD45RA+ T cellTh0 cellResting CD4+ T cell

Pharmacological agents typically target these cells by inhibiting T-cell receptor (TCR) signaling, blocking co-stimulatory pathways, or preventing cytokine-mediated signal transduction to arrest activation and differentiation.